Document is current
Any future updates will be listed below
-
Authors
John, Max Vincent
Simonitsch-Klupp, Ingrid
Griss, Johannes
Waldstein, Cora
Herrmann, Harald
Gaiger, Alexander
Gleixner, Karoline V.
Sperr, Wolfgang R.
Valent, Peter
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 16 August 2025
First Online: 6 September 2025
Declarations
:
: Max Vincent John: no COI reported; Ingrid Simonitsch-Klupp: Honoraria: Takeda; Johannes Griss: Personal fees: AbbVie, Eli Lilly, Pfizer, Boehringer Ingelheim, Almirall, and Novartis; Harald Herrmann: no COI reported; Cora Waldstein: no COI reported; Alexander Gaiger: no COI reported; Karoline V. Gleixner: Honoraria: Jazz pharmaceuticals, AbbVie, Novartis, Servier, Blueprint Medicines, Incyte, Celgene Corporation, Astellas, Daiichi Sankyo; Wolfgang R. Sperr: (1) Consultancy and Honoraria: Thermo Fisher, AbbVie, Novartis, Pfizer, BMS/Celgene, Blueprint, Incyte, Stemline, Servier, Jazz, Teva, (2) Research Grant: Pfizer; Peter Valent: (1) Research grant: AOP Orphan, (2) Advisory board and other consultant honoraria: Novartis, Blueprint Medicines, Cogent, Pfizer, AOP Orphan, Stemline.
: Written informed consent was obtained from the patient prior to sampling and storage of cells in a local biobank. The storage of cells was approved by the ethics committee of the Medical University of Vienna (approval number: 1184/2014). The patient gave written informed consent for publication of data and of the clinical photographs.
